Orlova Y, et al. - This study was pursued in order to gauge the risk of serotonin syndrome with concomitant use of triptans (antimigraine drugs) and selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI) antidepressants. Findings unveiled low risk of serotonin syndrome associated with concomitant use of triptans and SSRIs or SNRIs. It was reported that the coprescription of these drugs was common and did not decrease after the 2006 Food and Drug Administration (FDA) advisory. Yielded data cast doubt on the validity of the FDA advisory and recommended its reconsideration.